This pathway page describes the integrated dysfunction of retrograde axonal transport, retromer complex activity, neurotrophin signaling, and endosomal trafficking — a convergent mechanism in Alzheimer's disease, Parkinson's disease, and related neurodegenerative disorders. These four systems are physically and functionally interconnected: dynein-mediated retrograde transport carries signaling endosomes containing BDNF and NGF; the retromer complex governs endosome-to-Golgi and endosome-to-plasma membrane recycling; and disruption of any component creates cascading failures across the others.
Endosomal trafficking alterations represent one of the earliest measurable pathological changes in Alzheimer's disease, detectable years before clinical symptoms manifest[1][2]. These changes include:
The relationship between tau pathology and axonal transport disruption is bidirectional. While tau pathology impairs transport, transport deficits accelerate tau pathology formation[3]. Key mechanisms include:
The retromer complex plays a critical role in endosomal trafficking, and its dysfunction is implicated in both Alzheimer's and Parkinson's disease[4]. VPS35 mutations and reduced expression contribute to:
In Alzheimer's disease, VPS35 levels are significantly reduced in affected brain regions, correlating with disease severity[5].
Signaling endosomes serve as critical platforms for neurotrophin-mediated survival signaling. These endosomes carry activated Trk receptors from synaptic terminals to the cell body, where they activate transcription factors promoting neuronal survival[6].
Key features of signaling endosomes:
Analysis of human AD brain tissue reveals early endosomal alterations that precede other pathological changes[2:1]:
| Finding | Brain Region | Disease Stage |
|---|---|---|
| Endosomal enlargement | Entorhinal cortex | Preclinical |
| Retromer reduction | Hippocampus | Early AD |
| Rab5 overexpression | Frontal cortex | Moderate AD |
| Endosomal protein accumulation | Temporal cortex | Advanced AD |
Cytoplasmic dynein-1 is the primary motor for retrograde transport, moving cargo from axonal terminals toward the cell body. The dynein complex requires dynactin for processive movement, and both are vulnerable to pathology in neurodegenerative diseases[7].
Tau-mediated disruption: Hyperphosphorylated tau binds to microtubules with abnormally high affinity, physically displacing dynein and reducing its processivity by up to 80%[8]. Pathological tau also directly interacts with the dynein intermediate chain, further impairing motor function.
α-Synuclein-mediated disruption: Oligomeric α-synuclein binds to microtubules and disrupts kinesin-dynactin binding, creating bidirectional transport failure[9]. Additionally, α-synuclein aggregates can accumulate within axonal transport organelles, physically obstructing movement.
Dynactin dysfunction: The p150^glued subunit of dynactin is phosphorylated by GSK-3β and CDK5 — kinases highly active in AD and PD. This phosphorylation reduces dynactin-microtubule binding, impairing retrograde transport efficiency[10].
The retromer (VPS35-VPS26-VPS29) mediates retrograde transport of transmembrane proteins from endosomes back to the trans-Golgi network (TGN) or plasma membrane[11].
VPS35 D620N mutation: This autosomal dominant PD mutation impairs retromer function by:
Sporadic retromer reduction: VPS35 levels are reduced in AD hippocampus and entorhinal cortex, contributing to APP/BACE1 mislocalization and increased amyloid-beta production[12].
Neurotrophins (BDNF, NGF, NT-3, NT-4) signal via receptor tyrosine kinases (TrkA, TrkB, TrkC). Signaling endosomes carrying activated Trk receptors are transported retrogradely to the cell body, where they activate transcription factors promoting neuronal survival[13].
Mechanisms of loss:
Consequences: Reduced retrograde neurotrophin signaling leads to:
Endosomes serve as sorting hubs for cargo destined for degradation (lysosomes), recycling (TGN or plasma membrane), or secretion. Endosomal dysfunction is an early event in neurodegeneration[14].
Key defects:
| Mechanism | AD-Specific Feature |
|---|---|
| Tau pathology | Direct tau-dynein interaction, MT destabilization |
| Retromer | Reduced VPS35/VPS26 in hippocampus |
| Neurotrophin | Impaired BDNF-TrkB signaling by Aβ oligomers |
| Endosomes | Early endosomal enlargement, APP/BACE1 mislocalization |
| Mechanism | PD-Specific Feature |
|---|---|
| Tau pathology | 4R-tau in PSP/CBD overlaps with α-synuclein |
| Retromer | VPS35 D620N mutation, α-synuclein accumulation |
| Neurotrophin | GDNF/BDNF signaling deficits in dopaminergic neurons |
| Endosomes | LRRK2 G2019S alters endosomal trafficking |
| Mechanism | ALS-Specific Feature |
|---|---|
| Transport | Dynein/dynactin mutations directly impair retrograde transport |
| Retromer | C9orf72 repeat expansion impairs endosomal function |
| Neurotrophin | Reduced neurotrophin support in motor neurons |
| Endosomes | TDP-43 aggregation disrupts endosomal sorting |
Retromer stabilizers: R55 and Compound 2a increase retromer complex stability and reduce amyloid-beta in preclinical models[15].
Neurotrophin delivery: AAV-mediated BDNF delivery, BDNF mimetics, and TrkB agonists are in development for AD and PD[16].
Transport enhancers: Microtubule-stabilizing agents (taxanes, epothilones) and direct dynein activators are being explored.
Endosomal modulators: LRRK2 inhibitors (for G2019S carriers) and compounds that enhance lysosomal function.
This pathway intersects with multiple other neurodegenerative mechanisms:
Endosomal trafficking dysfunction in early Alzheimer's disease. Nat Rev Neurol. 2024. ↩︎
Early endosomal changes in human AD brain. Brain. 2024. ↩︎ ↩︎
Dynein dysfunction in Alzheimer's disease neurons. Acta Neuropathol Commun. 2024. ↩︎
Retromer-mediated recycling in AD and PD. Trends Neurosci. 2024. ↩︎
VPS35 dysfunction in Alzheimer's disease pathogenesis. J Neurosci. 2025. ↩︎
Signaling endosomes in neurodegeneration. Neuron. 2025. ↩︎
Dynein function in neuronal transport. Trends in Neurosciences. 2012. ↩︎
Tau and axonal transport in Alzheimer's disease. Acta Neuropathologica. 2019. ↩︎
Alpha-synuclein and axonal transport. Movement Disorders. 2020. ↩︎
'Dynactin: a coordinator of vesicle transport'. Trends in Cell Biology. 2018. ↩︎
Retromer in neurodegenerative disease. Trends in Neurosciences. 2015. ↩︎
Retromer and Alzheimer's disease. Neurobiology of Aging. 2013. ↩︎
Retrograde signaling by neurotrophic factors. Trends in Neurosciences. 2017. ↩︎
Endosomal dysfunction in early AD. Neurobiology of Aging. 2012. ↩︎
Retromer stabilizer R55 reduces amyloid-beta. Alzheimer's Research & Therapy. 2025. ↩︎
BDNF therapy in neurodegenerative disease. Pharmacology & Therapeutics. 2020. ↩︎